Professor Michaela Rumlová, head of a research group of the National Institute of Virology and Bacteriology at UCT Prague (and Vice-Rector for doctoral studies), holder of a licensed patent &nbsp;for antiretroviral testing assays, and recipient of the Czech Science Foundation’s President’s Award for HIV research, has also become the principal investigator of the bilateral INTER-EXCELLENCE II project “Cellular factors regulating the export and packaging of unspliced ​​retroviral RNA”, starting this year. In this interview, she explains how retroviruses such as HIV “hack” the cell in order to export their own genome from the nucleus into the cytoplasm, and then to the site where it is specifically packaged into nascent viral particles, a key step in viral replication. Her team is collaborating with the NIH (National Institutes of Health) and Rockefeller University to elucidate mechanisms that may help reveal new vulnerable points in the retrovirus replication cycle while simultaneously clarifying related cellular processes.<h5>Could you describe your project and its main objectives?</h5>Retroviruses, such as HIV, are viruses that carry genetic information in the form of RNA; however, after entering a cell, they are able to reverse transcribe it into DNA and integrate it into the host genome. In order to replicate, they must transport their genetic information—in the form of unspliced RNA—from the nucleus into the cytosol. There, it serves both as a template for the production of viral proteins and as the genome of new viral particles. This is highly unusual, as the cell very carefully controls which RNA molecules are allowed to leave the nucleus. Normal protein-coding cellular RNAs, known as messenger RNAs (mRNAs), must undergo splicing—a processing step in which certain segments are removed—before being exported. When this process fails, mRNA that retains these segments is held back in the nucleus as part of quality control and subsequently degraded. Retroviruses have managed to outwit this cellular control machinery, allowing their unspliced RNA to pass into the cytoplasm.Our project focuses on identifying the cellular proteins that assist retroviruses in this step and on the mechanism by which protein complexes bound to viral RNA are remodelled during RNA transport. The goal is to understand how the virus uses cellular mechanisms to its advantage and how this pathway is linked to the subsequent fate of the RNA, i.e. to its translation and packaging into new viral particles.<h5>Why is this export of unspliced ​​RNA so important for retroviral replication?</h5>Because this RNA has a dual role for the virus. On the one hand, it serves as a template for synthesizing viral proteins in the cytoplasm; on the other, it represents the genetic material itself, which must be packaged into new viral particles. The virus must package its RNA genome in its unspliced form, as only this RNA contains essential sequences without which further viral replication would be impossible.Simply put: the virus needs to get a complete copy of its genetic instructions out of the nucleus. Once the viral RNA is in the cytoplasm, it can be used as a template for synthesizing viral proteins; and a portion of these RNA molecules is then selected and packaged into a new particle as a genome. We are interested in how the virus forces the cell to allow viral RNA that is, from the cell’s perspective, “unfinished,” that is unspliced, to leave the nucleus. We are also investigating how the cell and the virus together - albeit unintentionally from the cell’s perspective - determine which RNA molecule will be translated into proteins and which will be packaged as the genome. This is one of the key, yet still not fully understood, steps of retroviral replication.<h5>What do you think it was about your project that impressed the Ministry of Education, Youth and Sports’ jury the most?</h5>I believe the decisive factor was a combination of several elements. First, the reviewers were primarily interested in the scientific problem itself. We are investigating a mechanism that is essential for retroviruses, but still not sufficiently understood, which may also have broader implications for the regulation of cellular processes. In addition, the quality of the team, our strong collaboration with the NIH and Rockefeller University, and the use of modern methods that will allow us to track viral RNA in great detail also played a role. It was also important that the project has clear objectives and a realistic plan.<h5>How will this research contribute to the development of new treatments for retroviral infections?</h5>It is important to say that this is primarily basic research. Rather than developing a new drug directly, we are trying to understand, at the molecular level, the step that the virus cannot do without. Only when we fully understand the mechanism of these cellular processes and identify the essential factors for the export of unspliced ​​RNA and how they function, will we be able to better determine which interactions or mechanisms represent potentially vulnerable points. Similar mechanisms associated with the export of unspliced ​​mRNA also appear in some diseases, such as cancer, so I &nbsp;see the benefit of our research mainly in that it will refine our understanding of these pathological processes in the cell, and retroviruses help us do so. Therefore, our work on retroviruses not only shows us how the virus works, but also how the cell itself works.<h5>What responsibilities does your UCT Prague team have? How does the collaboration with your American partners work?</h5>At UCT Prague, we are conducting the project’s primary experimental work. Our research involves cell cultures, viral models, and various biochemical techniques ranging from immunochemistry to microscopy that allow us to track viral RNA and identify its cellular partners. In collaboration with colleagues from NIH, Frederick, we are developing single-particle tracking methods to observe viral RNA movement in living cells across both space and time. Furthermore, we are working with colleagues from Rockefeller University to employ iCLIP methods for the precise mapping of protein-binding sites on RNA. Both collaborations are valuable to us, because they are not just about data sharing, but also about the transfer of expertise and detailed know-how.<h5>Who else is collaborating on the project?</h5>At UCT Prague, we collaborate closely with the Department of Biotechnology and the Department of Biochemistry and Microbiology. Externally, we work with colleagues from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) and the Central European Institute of Technology in Brno (CEITEC). Our research naturally necessitates the integration of diverse fields of expertise; it requires combining virology, cell biology, and biochemistry with advanced imaging and modern approaches to study RNA-protein interactions. This is exactly what makes our project capable of addressing complex questions that a single laboratory cannot tackle on its own.<h5>Are there plans to continue the project? Have you brought on new collaborators, and are you looking to welcome new colleagues to the team?</h5>Yes, definitely. In basic research, it often happens that one answered question opens up several more. High-quality, properly interpreted data provide a foundation you can build on — and that is what moves scientists forward. It is already clear that the topic of retroviral RNA export and packaging has broader implications and may reveal more general principles of how RNA functions within the cell. We also hope the project will be attractive to students, as it connects classical molecular biology, biochemistry, and virology with cutting-edge biotechnological methods. Students are already involved in the project as part of their bachelor’s and master’s theses.<h5>What was the personal turning point that motivated you to pursue a long-term investigation into retroviral particles?</h5>I first encountered retroviruses in the early 1990s during my diploma thesis, when I was working at IOCB Prague on HIV-1 protease inhibitors. At that time, AIDS could not yet be effectively treated, and retrovirus research had a completely different dimension. From the very beginning, I was fascinated by how such a relatively small and simple virus can outsmart evolutionarily highly optimized cellular processes and turn them to its own advantage. And that has never stopped fascinating me. From a scientific point of view, retroviruses are remarkable; just consider one of their enzymes, reverse transcriptase, without which no diagnostic or research laboratory in the world could function today. Without it, it would be impossible to diagnose RNA viruses like SARS-CoV-2, influenza, or HIV using RT-PCR tests, or, for example to produce recombinant human proteins in bacterial cells.

Tracking unspliced RNA: Professor Rumlová studies how retroviruses “hack” cells

High-performance liquid chromatography (HPLC) remains one of the most widely used analytical techniques for separating, identifying, and quantifying compounds in complex mixtures. Successful HPLC method development depends not only on selecting the correct column and optimizing the mobile phase composition, but also on choosing the appropriate detector. Even a perfectly optimized chromatographic separation provides little value if the detection system cannot properly capture and interpret the analytes of interest.In many ways, the detector acts as the “vision system” of the chromatograph. It converts separated compounds into measurable electronic signals, allowing analysts to identify components and determine their concentrations. The choice of detector therefore has a major impact on sensitivity, selectivity, robustness, and the overall quality of analytical data.This article provides an overview of the most common HPLC detection techniques, discusses their strengths and limitations, and outlines the most important criteria to consider when selecting a detector for a specific analytical task.<h3>HPLC Detection Technologies</h3>HPLC detectors are typically divided into two major categories:<ol><li>Specific detectors (solute-property detectors)</li><li>Bulk property detectors</li></ol>Specific detectors respond to a particular chemical or physical property of the analyte. Ideally, their signal is largely unaffected by changes in mobile phase composition. Common examples include UV/Vis detectors, fluorescence detectors, and mass spectrometers.Bulk property detectors, on the other hand, measure differences between the pure mobile phase and the mobile phase containing analytes. These detectors are considered more universal because they respond to properties shared by many compounds. Refractive index detectors are among the best-known examples, alongside conductivity and light-scattering detectors.Both detector categories have important advantages depending on the application, sample type, and analytical goals.<h3>Common Detector Types Used in HPLC</h3>A wide variety of detectors are available for HPLC systems, ranging from highly universal devices to extremely selective and sensitive technologies.Common detector options include:<ul><li>UV/Vis detectors</li><li>Diode array detectors (DAD/PDA)</li><li>Fluorescence detectors</li><li>Refractive index detectors (RID)</li><li>Conductivity detectors</li><li>Evaporative light scattering detectors (ELSD)</li><li>Charged aerosol detectors (CAD)</li><li>Mass spectrometry detectors (MS)</li></ul>Each technology offers a different balance of sensitivity, selectivity, robustness, operational complexity, and cost.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Detector_overview_with_characteristics_Graphic_by_KNAUER_84b0dd30b1.jpg" alt="KNAUER: Detector overview with characteristics. Graphic by KNAUER." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Detector_overview_with_characteristics_Graphic_by_KNAUER_84b0dd30b1.jpg 245w," sizes="100vw" width="1293" height="596"><h3>Selecting the Right HPLC Detector</h3>There is no universally ideal detector for all HPLC applications. The best choice depends on several factors, including analyte chemistry, matrix complexity, required detection limits, and instrument compatibility.Careful detector selection is essential for obtaining reliable and meaningful analytical results.The following considerations can help guide the selection process.<h4>1. Chemical and Physical Properties of the Analytes</h4>The chemical nature of the compounds being analyzed is one of the most important selection criteria.Questions to consider include:<ul><li>Do the analytes contain chromophores?</li><li>Are the compounds naturally fluorescent?</li><li>What is their polarity?</li><li>What is their molecular weight?</li><li>Are they volatile or non-volatile?</li></ul>Compounds containing UV-active groups are often well suited for UV/Vis detection, while fluorescent molecules can benefit from the high sensitivity of fluorescence detectors. Non-UV-active compounds may require universal detection approaches such as CAD, ELSD, or mass spectrometry.<h4>2. Required Sensitivity</h4>Detector sensitivity determines the minimum concentration that can be reliably detected and quantified.Routine quality control analyses often rely on UV/Vis detectors because they provide sufficient sensitivity for many applications while remaining relatively simple and cost-effective. However, trace-level analysis or highly complex matrices may require more advanced technologies such as:<ul><li>Fluorescence detection</li><li>Charged aerosol detection</li><li>Mass spectrometry</li></ul>These techniques offer significantly lower detection limits and greater analytical specificity.<h4>3. Detector Linearity</h4>Linearity describes how well detector response correlates with analyte concentration across a defined range.A detector with strong linearity ensures accurate quantification and simplifies calibration procedures. Poor linearity can introduce quantification errors, especially when analyzing samples across broad concentration ranges.<h4>4. Dynamic Range</h4>Dynamic range refers to the concentration interval over which the detector can reliably measure analytes.Applications involving samples with highly variable concentrations require detectors capable of maintaining accurate response over a broad range. A wide dynamic range reduces the need for repeated dilutions or multiple analytical runs.<h4>5. Selectivity</h4>Selectivity defines the detector’s ability to distinguish target analytes from other matrix components.This factor becomes particularly important for complex samples containing many interfering substances. Highly selective detectors reduce the risk of overlapping signals and false positives.Mass spectrometry is often advantageous when dealing with unknown compounds or highly complicated sample matrices because it provides structural information in addition to quantitative data.<h4>6. Budget Considerations</h4>Detector cost is another practical factor that laboratories must evaluate.UV/Vis and refractive index detectors are generally among the more economical choices, making them attractive for routine analyses and standard applications.More sophisticated technologies such as fluorescence detection, CAD, or mass spectrometry typically require:<ul><li>Higher initial investment</li><li>Additional maintenance</li><li>More complex infrastructure</li><li>Greater operational expertise</li></ul>However, the overall value of the detector should always be considered in relation to analytical performance requirements and long-term application needs.<h4>7. Instrument and Mobile Phase Compatibility</h4>The selected detector must be compatible with the operational conditions of the HPLC system.Important parameters include:<ul><li>Flow rate range</li><li>Pressure limitations</li><li>Mobile phase composition</li><li>Solvent compatibility</li></ul>Some detectors are highly sensitive to mobile phase composition or gradient changes, while others tolerate a broader range of operating conditions.Ensuring proper compatibility helps prevent baseline instability, signal interference, and reduced detector performance.<h4>8. Destructive vs. Non-Destructive Detection</h4>Another important consideration is whether the analytical workflow involves only detection or also preparative purification.Non-destructive detectors allow collected fractions to remain intact after detection, which is highly beneficial for preparative chromatography and purification workflows.Destructive detectors, by contrast, consume or alter the sample during measurement and are therefore more suitable for analytical applications where sample recovery is not required.<h4>9. Reliability and Ease of Operation</h4>Practical usability is often just as important as analytical performance.Some detectors are designed for straightforward plug-and-play operation, while others require:<ul><li>Frequent calibration</li><li>Specialized maintenance</li><li>Dedicated gas supplies</li><li>Vacuum systems</li><li>Advanced operator expertise</li></ul>Laboratories should evaluate the available technical support, user experience, and maintenance capabilities before implementing more sophisticated detection technologies.Reliable operation and manageable maintenance requirements can significantly improve laboratory productivity and reduce downtime.Choosing the correct HPLC detector starts with understanding both the sample and the analytical objective. Rather than selecting a detector simply because it is available, laboratories should ensure that the technology aligns with the chemistry of the analytes, required performance characteristics, and workflow demands.In many cases, combining multiple detectors within a single HPLC system can provide even greater analytical insight by delivering complementary information from the same chromatographic separation.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/KNAUER_Flow_scheme_for_detector_selection_Graphic_by_KNAUER_486004045f.jpg" alt="KNAUER: Flow scheme for detector selection. Graphic by KNAUER." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_KNAUER_Flow_scheme_for_detector_selection_Graphic_by_KNAUER_486004045f.jpg 245w," sizes="100vw" width="1316" height="808">Interested in learning more? Future articles will explore individual HPLC detection techniques in greater detail, including their operating principles, application areas, and practical advantages for different analytical workflows.

A comprehensive guide for selecting the appropriate HPLC detector

News from LabRulezLCMS Library - Week 20, 2026

Article

Product

Application

Scientists

Science and research

The University of Chemistry and Technology, Prague is a natural centre of first-rate study and research in the area of chemistry in Czechia and is one of the country's largest educational and research institutions focused on technical chemistry, chemical and biochemical technologies, material and chemical engineering, food chemistry, and environmental studies.

UCT Prague

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Based in Berlin, KNAUER is a medium-sized, owner-managed company that has been serving the sciences since 1962. We develop and manufacture scientific instruments of superior quality for liquid chromatography, including: Analytical HPLC/UHPLC, Preparative HPLC, Fast protein liquid chromatography (FPLC), Multi-column chromatography/Simulated moving bed (SMB) chromatography. High pressure dosing, in-line detection systems, and osmometry are additional business areas.

KNAUER

Agilent Technologies

The meeting will dive into the topic of Dissolution Testing of semisolid formulations and spotlight on the most relevant instruments/accessories available. We will also discuss some tips and tricks for the method development of semisolids.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Agilent Technologies: Revisions to USP chapter 1724 - Dissolution Testing of Semisolids

Revisions to USP chapter 1724 - Dissolution Testing of Semisolids

Join us to get an update on the latest changes and additions to USP chapter <1724>.

Rev. to USP chapter 1724 - Dissolution Testing of Semisolids

Join the DDG expert panel for an update on the Key Regulatory and Compendial Dissolution Updates from 2021. With our busy lives it is always difficult to find time to scan all the regulatory bodies for news, so this a great opportunity to get yourself up-to-date on the regulatory topic. Bryan Crist, our panel member, brings many years of experience working on various USP committees to this meeting and supports the discussion of the latest updates and what they mean for your day-to-day work.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Agilent Technologies: What You (May) Have Missed: Key Regulatory and Compendial Dissolution Updates in 2021

What You (May) Have Missed: Key Regulatory and Compendial Dissolution Updates in 2021

Join the DDG expert panel for an update on the Key Regulatory and Compendial Dissolution Updates from 2021.

Key Regulatory and Compendial Dissolution Updates in 2021

Lipid nanoparticles, nanospheres, nanocrystals, liposomes, dendrimers, Iscoms…what are all these different particles? What do they have in common? What makes them so attractive for the delivery of drugs, as parenteral delivery systems and especially for the delivery of vaccines? Why are dissolution studies so challenging with these particulate carriers? Let’s take a closer look at all these questions and try to answer them with our group of experts from the DDG panel and industry experts.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Exploring Dissolution Techniques for Vaccines, Liposomes, and Parenterals

Let’s take a closer look at all these questions and try to answer them with our group of experts from the DDG panel and industry experts.

Dissolution for Vaccines, Liposomes, and Parenterals

While solid dosage forms like tablets are still the widely used option for the delivery of medication, there is an increasing need for alternative dosage forms. Medical devices are on the rise and when combined with a drug, they most likely also need to undergo dissolution testing, which can be challenging with the conventional apparatus. Many novel dosage forms, e.g. electro spun fleeces, microneedle patches, implants also require modifications to the dissolution apparatus we know. Join us for a discussions on these challenges and how they can be overcome.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Agilent Technologies: Current Practices for the Dissolution Testing of Medical Devices, Combination Products, and Novel Dosage Forms

Current Practices for the Dissolution Testing of Medical Devices, Combination Products, and Novel Dosage Forms

Join us for a discussions on challenges and how they can be overcome.

Practices for the Dissolution Testing of Medical Devices

Development of veterinary products is a challenge in itself. Animal ranges from very small to very large, so how to accommodate the large dosage range? Special flavors need to be added. What dosage forms are accepted by animals? Thinking about this, you can imagine, that dissolution testing of these products can present a real challenge. Let’s take a trip to the vet and explore our options.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Agilent Technologies: A Trip to the Vet: Expert Advice about Dissolution Testing of Veterinary Products

LCMS webinars focusing on Dissolution - page 3